ClinicalTrials.gg
Not yet recruitingNCT07723105DIGI-CONSENTUpdated Jul 23, 2026

Digital-Supported Versus Standard Consent for Advanced Therapeutic Endoscopy

An interventional study of Digital-Supported Informed Consent Pathway and Standard Physician-Led Informed Consent in Informed Consent, Patient Education and Patient Comprehension, sponsored by Unity Health Toronto. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by Unity Health Toronto · Not applicable, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Patient Satisfaction with a site in Canada — 6 open to participants now, 9 under way, none of them phase 3. Patient Satisfaction · Canada.

Planned enrollment
15th of 43
180 · median 101
Started
2026
with 3 others
No phase
41 of 49
5 open now
Registered
49th of 49
by date
Lead sponsor
2 of 49
Unity Health Toronto

Among the 49 studies in Patient Satisfaction with a site in Canada, this one is the 15th largest by planned enrollment of the 43 interventional ones that give a count, is one of 4 that started in 2026, is one of 41 with no phase, and was the 49th registered.

Patient Satisfaction

882 studies on the registry are indexed under Patient Satisfaction; 205 are open to participants now.

Browse Patient Satisfaction studies →

Open to participants now

6 of the 49 studies in Patient Satisfaction with a site in Canada are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 102 Patient Satisfaction studies recruiting now, 63 (62%) set no upper age limit and 31 (30%) stop at 75 or younger; 14 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Patient Satisfaction with a site in Canada, or all of them as a file.
02

Study summary

This study will evaluate whether a digital-supported informed consent process improves patient understanding before advanced therapeutic endoscopy procedures.

Patients undergoing advanced therapeutic endoscopy are often asked to make decisions about procedures that may be complex and involve important risks, benefits, and alternatives. Standard informed consent is usually provided through discussion with the treating physician. However, this process can vary between clinicians and may be affected by time pressures in busy endoscopy units.

In this study, eligible adult patients scheduled for elective advanced therapeutic endoscopy will be randomly assigned to one of two consent pathways. One group will receive standard physician-led informed consent. The other group will receive a digital-supported consent pathway that includes a standardized procedure-specific educational video, an offline artificial intelligence-based question-answering tool, and final confirmation with the treating physician before the procedure.

The digital tool is designed to provide plain-language information about the procedure, including why it is being done, expected benefits, common and serious risks, alternatives, what to expect before and after the procedure, and the patient's right to ask questions or decline the procedure. The AI question-answering tool will use only investigator-approved educational content and will not provide individualized medical advice. Questions requiring patient-specific medical judgment will be directed back to the treating clinical team.

The main outcome of the study is patient comprehension of the consent information, measured after the assigned consent process and before the procedure. The study will also evaluate patient anxiety, satisfaction, confidence in decision-making, usability of the consent process, workflow outcomes, and consent-related safety or ethical concerns.

Read the detailed description

This is a pragmatic multicenter randomized controlled trial evaluating digital-supported informed consent compared with standard physician-led informed consent for adults undergoing elective advanced therapeutic endoscopy.

The study will be conducted in three sequential phases. In the first phase, the digital consent tool will be developed through an iterative co-design process involving the study team, a specialist engineer, and at least one patient partner. The tool will include a standardized procedure-specific educational video and an offline artificial intelligence-based question-answering interface. The AI component will be developed using only investigator-approved educational materials, standardized consent language, and curated frequently asked questions. It will not browse the internet, retrieve external information in real time, or provide individualized medical advice.

In the second phase, a pilot study will assess feasibility, usability, acceptability, and operational performance of the digital consent pathway. The pilot will assess whether participants can access and complete the video and AI interface, whether the digital tool functions as intended, whether the survey-based outcome assessment workflow is practical, and whether refinements are needed before the full randomized trial. The pilot phase is not intended to provide definitive comparative effectiveness results.

In the third phase, the finalized intervention will be evaluated in a multicenter, parallel-group randomized controlled trial. Eligible participants will be randomized in a 1:1 ratio to either standard physician-led informed consent or the digital-supported consent pathway. Randomization will be centralized and concealed using a secure web-based system, with stratification by site and potentially by major procedure category.

Participants assigned to the standard consent arm will receive the usual physician-led informed consent process according to local clinical practice. Participants assigned to the digital-supported arm will receive access to a procedure-specific digital consent package, ideally before the procedure. The digital package will include a standardized educational video explaining the nature of the procedure, the reason it is being performed, expected benefits, major and common risks, reasonable alternatives, what to expect before and after the procedure, and the right to ask questions or decline the procedure. After viewing the video, participants may ask questions through a secure offline AI-based interface. The tool will provide plain-language responses grounded only in pre-approved study materials and will redirect individualized or high-risk questions to the treating clinical team.

In both study arms, final procedural consent remains the responsibility of the treating physician. In the digital-supported arm, the physician will conduct a final confirmation discussion before the procedure to review unresolved questions, address individualized risks, benefits, and alternatives, confirm patient understanding, and complete standard institutional consent documentation.

The primary outcome is patient comprehension of informed consent information, assessed immediately after completion of the assigned consent pathway and before the procedure. The comprehension assessment will address key domains of informed consent, including the nature of the procedure, indication, risks, benefits, alternatives, right to ask questions or refuse, and basic expectations before and after the procedure.

Secondary outcomes include pre-procedural anxiety, satisfaction with the consent process, decisional confidence or self-efficacy, perceived usability and acceptability, perceived opportunity to ask questions, preference for future consent format, physician time spent on consent, staff time where measurable, consent-related delays, same-day cancellation or deferral due to unresolved consent concerns, and need for additional pre-procedural contact related to consent. Digital process outcomes will include video completion rate, AI tool utilization rate, number and categories of patient questions, frequency of questions escalated to clinician review, and completion of the intervention before arrival. Safety and ethical quality outcomes will include withdrawal of procedural consent after the assigned intervention, patient-reported misunderstanding, complaints related to the consent process, protocol deviations involving consent, and any adverse event judged related to misunderstanding of instructions or procedural expectations.

The study is designed to minimize collection of identifiable information. Study outcomes will be collected primarily through secure survey links, and the research dataset will not include direct identifiers such as names, dates of birth, medical record numbers, addresses, email addresses, telephone numbers, or IP addresses. Any retained AI interaction data will be anonymized and will not be linked to participant identifiers.

03

Conditions studied

  • Informed Consent
  • Patient Education
  • Patient Comprehension
  • Therapeutic Endoscopy
  • Digital Health

Browse trials for

Keywords

  • Digital consent
  • Informed consent
  • Advanced endoscopy
  • Therapeutic endoscopy
  • Patient comprehension
  • Patient education
  • Artificial intelligence
  • AI question-answering tool
  • Video-based consent
  • Patient satisfaction
  • Pre-procedural anxiety
  • Pragmatic randomized trial
  • Endoscopy workflow
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older
  • Scheduled to undergo elective advanced therapeutic endoscopy
  • Able to provide for study participation
  • Able to engage with study materials in a language supported by the site
  • Willing and able to complete study questionnaires and follow-up assessments

Exclusion criteria

Exclusion Criteria:

  • Emergent or urgent procedures where the consent process cannot reasonably incorporate the study intervention
  • Inability or unwillingness to provide for study participation
  • Requirement for substitute decision-maker consent for the procedural decision itself, if this precludes meaningful use of the study intervention
  • Severe cognitive, visual, hearing, or communication limitations not adequately accommodated by site resources
  • Inability to complete the planned pre-procedural assessments
  • Prior enrollment in this study for the same procedural episode
  • Any clinical situation in which the treating endoscopist determines that study participation would be unsafe or inappropriate
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Digital-Supported Informed Consent

    Participants assigned to this arm will receive a digital-supported informed consent pathway before elective advanced therapeutic endoscopy. The pathway includes a standardized procedure-specific educational video, an offline AI-based question-answering tool using investigator-approved content, and final physician confirmation before the procedure. The treating physician remains responsible for individualized risk discussion and final procedural consent.

    Behavioral: Digital-Supported Informed Consent Pathway

  • Active comparator
    Standard Physician-Led Informed Consent

    Participants assigned to this arm will receive the usual physician-led informed consent process before elective advanced therapeutic endoscopy according to local clinical practice. The treating physician will review the procedure, risks, benefits, alternatives, and patient questions, and will complete standard institutional procedural consent documentation.

    Behavioral: Standard Physician-Led Informed Consent

Interventions

  • BehavioralDigital-Supported Informed Consent Pathway

    The digital-supported informed consent pathway consists of a standardized procedure-specific educational video, an offline AI-based question-answering interface, and final physician confirmation. The video explains the nature of the procedure, indication, expected benefits, major and common risks, alternatives, what to expect before and after the procedure, and the patient's right to ask questions or decline. The AI tool provides plain-language responses based only on investigator-approved educational materials and redirects individualized or high-risk questions to the treating clinical team.

    Also known as: Digital consent pathway, Video and AI-supported consent

  • BehavioralStandard Physician-Led Informed Consent

    The standard physician-led informed consent process consists of usual pre-procedure counseling by the treating physician according to local clinical practice. The physician discusses the procedure, indication, expected benefits, risks, alternatives, and patient questions, and completes standard institutional procedural consent documentation before the advanced therapeutic endoscopy procedure.

    Also known as: Usual consent, Standard consent process

06

What researchers measure

Primary outcomes

  1. Patient Comprehension of Informed Consent Information

    Patient comprehension will be assessed using a structured procedure-specific comprehension instrument after the assigned consent pathway. The instrument will assess understanding of the nature of the procedure, purpose or indication, risks, benefits, alternatives, right to ask questions or refuse, and expectations before and after the procedure.

    Time frame: Immediately after the assigned consent pathway and before sedation/procedure

Secondary outcomes

  1. Pre-Procedural Anxiety

    Participant-reported anxiety after completion of the assigned consent pathway, assessed using a study questionnaire or validated anxiety measure, as finalized in the study assessment plan.

    Time frame: Immediately after the assigned consent pathway and before sedation/procedure

  2. Satisfaction With Consent Process

    Participant-reported satisfaction with the assigned consent process, including perceived clarity and helpfulness of the information provided.

    Time frame: Immediately after the assigned consent pathway and before sedation/procedure

  3. Decisional Confidence or Self-Efficacy

    Participant-reported confidence in the decision to proceed with the procedure and perceived ability to make an informed decision after the consent process.

    Time frame: Immediately after the assigned consent pathway and before sedation/procedure

  4. Usability and Acceptability of Consent Process

    Participant-reported usability and acceptability of the assigned consent process. For participants in the digital-supported arm, this will include perceived usability and acceptability of the video and AI-based question-answering tool.

    Time frame: Immediately after the assigned consent pathway and before sedation/procedure

  5. Perceived Opportunity to Ask Questions

    Participant-reported perception of whether they had adequate opportunity to ask questions and have concerns addressed during the consent process.

    Time frame: Immediately after the assigned consent pathway and before sedation/procedure

  6. Preference for Future Consent Format

    Participant preference for future consent format, including whether they would prefer standard physician-led consent, digital-supported consent, or a combined approach in future procedures.

    Time frame: Immediately after the assigned consent pathway and before sedation/procedure

  7. Physician Time Spent on Consent

    Total physician time spent on the consent process, measured where feasible using workflow tracking or routine operational data.

    Time frame: From start to completion of the consent process on the procedure day

  8. Consent-Related Staff Time

    Total staff time related to the consent process, where measurable using workflow tracking or routine operational data.

    Time frame: From start to completion of the consent process on the procedure day

  9. Consent-Related Delay

    Delay attributable to the consent process, measured where feasible using routine operational or workflow data.

    Time frame: Procedure day, before procedure start

  10. Same-Day Cancellation or Deferral Due to Consent Concerns

    Proportion of participants whose procedure is canceled or deferred on the same day because of unresolved consent-related concerns.

    Time frame: Procedure day

  11. Additional Pre-Procedural Contact Related to Consent

    Need for additional pre-procedural contact with the clinical or research team related to consent questions or concerns.

    Time frame: From enrollment to procedure start

  12. Video Completion Rate

    Proportion of participants assigned to the digital-supported arm who complete the standardized procedure-specific educational video.

    Time frame: Before procedure start

  13. AI Tool Utilization Rate

    Proportion of participants assigned to the digital-supported arm who use the offline AI-based question-answering tool.

    Time frame: Before procedure start

  14. Number and Categories of Patient Questions Asked

    Number and categories of questions submitted by participants through the digital question-answering interface.

    Time frame: Before procedure start

  15. Frequency of Questions Escalated to Clinician Review

    Number and proportion of participant questions that are flagged as individualized, complex, high-risk, or requiring clinician review.

    Time frame: Before procedure start

  16. Digital Intervention Completion Before Arrival

    Proportion of participants assigned to the digital-supported arm who complete the digital consent pathway before arrival for the procedure.

    Time frame: Before arrival for procedure

  17. Withdrawal of Procedural Consent After Assigned Intervention

    Proportion of participants who withdraw procedural consent after completing the assigned consent pathway.

    Time frame: After assigned consent pathway through procedure start

  18. Questionnaire Assessing Patient Understanding

    Participant-reported misunderstanding related to the consent information, procedure instructions, or procedural expectations identified after the procedure.

    Time frame: immediately after the intervention

  19. Complaints Related to Consent Process

    Number of participant complaints related to the consent process.

    Time frame: immediately after the intervention

  20. Protocol Deviations Involving Consent

    Number of protocol deviations related to delivery or documentation of the study consent or procedural consent process.

    Time frame: From enrollment through study follow-up

  21. Adverse Events Related to Misunderstanding of Instructions or Procedural Expectations

    Any adverse event judged to be related to misunderstanding of procedural instructions or expectations following the assigned consent pathway.

    Time frame: immediately after the intervention

Other outcomes

  1. Retention of Key Knowledge

    Participant retention of key consent-related knowledge at short follow-up after the procedure.

    Time frame: immediately after the intervention

  2. Subgroup Differences in Comprehension and Consent Outcomes

    Exploratory subgroup analyses by age, education, prior endoscopy experience, digital literacy, procedure type, and site.

    Time frame: immediately after the intervention

  3. Comparative Performance Across Study Settings

    Exploratory comparison of intervention performance across North American and European participating sites.

    Time frame: immediately after the intervention

07

Study locations

1 site
08

References and documents

Publications

  • Padival R, Harris KB, Garber A, El-Khider F, Kichler A, Vargo J, Baggott BB. Video Consent for Colonoscopy Improves Knowledge Retention and Patient Satisfaction: A Randomized Controlled Study. J Clin Gastroenterol. 2022 May-Jun 01;56(5):433-437. doi: 10.1097/MCG.0000000000001589. PubMed 34319948 ↗
  • Hall DE, Prochazka AV, Fink AS. Informed consent for clinical treatment. CMAJ. 2012 Mar 20;184(5):533-40. doi: 10.1503/cmaj.112120. Epub 2012 Mar 5. No abstract available. PubMed 22392947 ↗
  • Agre P, Kurtz RC, Krauss BJ. A randomized trial using videotape to present consent information for colonoscopy. Gastrointest Endosc. 1994 May-Jun;40(3):271-6. doi: 10.1016/s0016-5107(94)70054-0. PubMed 8056226 ↗
  • Xia T, Zhu YB, Zeng YB, Chen C, Wang SL, Zhao SB, Su XJ, Wang D, Yao J, Li ZS, Bai Y. Video education can improve awareness of risks for patients undergoing endoscopic retrograde cholangiopancreatography: A randomized trial. J Dig Dis. 2019 Dec;20(12):656-662. doi: 10.1111/1751-2980.12824. Epub 2019 Nov 21. PubMed 31618520 ↗
  • Tan CM, Bernstein M, Raboud J, Mannino B, Tinmouth J. Efficiency in the Endoscopy Unit: Can We 'Turn Around' Room Turnover? An Observational Quality Improvement Study. J Can Assoc Gastroenterol. 2022 Mar 10;5(4):e57-e64. doi: 10.1093/jcag/gwac005. eCollection 2022 Aug. PubMed 35919763 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared because the study is designed to collect anonymous, non-identifiable survey-based data without direct participant identifiers or a participant linking log. The protocol does not include a formal plan for external sharing of participant-level data. Aggregate study results may be reported in publications and presentations.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2027, 15 months later.

Of 368 non-industry interventional studies with no phase under Patient Satisfaction, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 15 months is above that.

Counting every sponsor, half of 370 studies reached it within 12 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2026
First posted
Jul 23, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Dec 1, 2027
CompletionEst.
Mar 1, 2028
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07723105
Responsible party
Natalia Calo (Assistant Professor, Unity Health Toronto) — Principal investigator
First posted
Jul 23, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Dec 1, 2027 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
Jul 23, 2026

Study contacts

Kareem Khalaf, MD
Contact
kareem.khalaf@unityhealth.to
+1-416-360-4000 ext. 77537
Kareem Khalaf, MD
Contact
kareem.khalaf@unityhealth.to
Natalia Causada Calo
principal investigator · Division of Gastroenterology, St. Michael's Hospital, Unity Health Toronto, University of Toronto, Toronto, Ontario, Canada

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion